▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #419 by analyst upside · 2026-06-27
SPRY
ARS Pharmaceuticals, Inc.
Healthcare · Market Cap $848M · P/E 0x
ANALYST PRICE TARGET
+232.6%
implied upside to consensus target
Current Price $8.54
Consensus Target $28.4
Bull Target $32.0
Bear Target $24.0
Analysts Covering 5
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
5
Hold
0
Sell
0
52-Week Low $6.66
52-Week High $18.9
YTD Return -25.7%
FUNDAMENTALS
Market Cap $848M
P/E Ratio (TTM) N/A
Forward P/E -10.3x
EPS (TTM) $-2.11
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $99M
Profit Margin -200.0%
52-WEEK RANGE
52-Week Low $6.66
52-Week High $18.9
Current Price $8.54
Bear Target $24.0
Bull Target $32.0
● Now $8.54 ● Target $28.4
TRADING DATA
Avg Volume 1.8M
YTD Return -25.7%
Analyst Count 5
Consensus Buy
Upside to Target +232.6%
Last Updated 2026-06-27

ANALYST SUMMARY

ARS Pharmaceuticals, Inc. (SPRY) is currently trading at $8.54 with a Wall Street consensus price target of $28.4, implying potential upside of 232.6% over the next 12 months. 5 analysts currently cover SPRY, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $32.0, while the most cautious has a target of $24.0.

SPRY operates in the Healthcare sector with a market capitalisation of $848M. The stock is down 25.7% year-to-date and is currently trading near the lower end of its 52-week range of $6.66 – $18.9.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ABEO +251.4%
Abeona Therapeutics Inc.
$320M · P/E 5.9x · Buy
PHAR +157.5%
Pharming Group N.V.
$942M · P/E 70.2x · Buy
NAGE +268.4%
Niagen Bioscience, Inc.
$272M · P/E 16.3x · Buy
ZVRA +106.3%
Zevra Therapeutics, Inc.
$799M · P/E 6.6x · Buy
HCM +124.5%
HUTCHMED (China) Limited
$2B · P/E 3.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for SPRY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald — Reiterated
Overweight → Overweight 2026-05-28 40% win rate (10 calls)
Roth Capital ● Initiated
Buy 2025-09-04 Building track record
Scotiabank ● Initiated
Sector Outperform 2025-03-07 20% win rate (5 calls)
Raymond James — Reiterated
Strong Buy → Strong Buy 2025-01-14 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2025-01-13 29% win rate (7 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-10-08 40% win rate (10 calls)
Leerink Partners — Reiterated
Outperform → Outperform 2024-09-20 29% win rate (7 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-16 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →